Toggle Bio — SEC Form D Filing

Toggle Bio filed an SEC Form D on October 6, 2026, reporting $200K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 6, 2026
Amount reported
$200K
Round stage
Pre-seed because a $200,000 raise via SAFEs is typical for early-stage proof-of-concept and initial IP filing in biotechnology.
Industry
Biotechnology
Website
https://toggle.bio

What the company does

Securities: SAFEs. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Traditional gene therapies and biologics lack precise, reversible control mechanisms, leading to off-target toxicity and limited therapeutic windows.

Solution

Toggle Bio develops programmable synthetic biology switches that allow researchers and clinicians to precisely toggle gene expression and therapeutic activity on and off.

Why now

Recent advancements in CRISPR, synthetic gene circuits, and precision medicine have created an urgent demand for dynamic control systems to make cell and gene therapies safer.

Source: SEC EDGAR Form D filing